

WEST**Freeform Search****Database:**

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:

11 and 12

Display:

20

Documents in **Display Format:** -

Starting with Number

20

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

Search History**DATE:** Thursday, November 21, 2002 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
<u>L3</u>	11 and 12	4	<u>L3</u>
<u>L2</u>	cox-2	1206	<u>L2</u>
<u>L1</u>	scutellaria baicalensis	265	<u>L1</u>

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul88mxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:10:43 ON 21 NOV 2002

=> ile ca, medline, biosis
ILE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CA' ENTERED AT 17:11:05 ON 21 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:11:05 ON 21 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 17:11:05 ON 21 NOV 2002

=> s scutellaria baicalensis?
L1 814 SCUTELLARIA BAICALENSIS?

=> s cox-2?
TERM '2?' EXCEEDED TRUNCATION LIMITS - SEARCH ENDED

<-----User Break----->

u

SEARCH ENDED BY USER

You have entered a truncated stem which occurs in too many terms.
Make the stem longer and try again. For example, if your original
term was 'degr?' to search for variations and the abbreviation for
'degradation', you could replace it with the expression '(degrdn OR
degrad?)'. If your search term was numeric, e.g., 'C>5', reduce the
size of the range.

=> d his

(FILE 'HOME' ENTERED AT 17:10:43 ON 21 NOV 2002)

FILE 'CA, BIOSIS, MEDLINE' ENTERED AT 17:11:05 ON 21 NOV 2002
L1 814 S SCUTELLARIA BAICALENSIS?

=> s cox-2
L2 12387 COX-2

=> s l1 and l2
L3 1 L1 AND L2

=> d

L3 ANSWER 1 OF 1 CA COPYRIGHT 2002 ACS

AN 135:102178 CA
 TI Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide
 AU Chen, Y.-C.; Shen, S.-C.; Chen, L.-G.; Lee, T. J.-F.; Yang, L.-L.
 CS Graduate Institute of Pharmacognosy Science, Taipei Medical University, Taipei, Taiwan
 SO Biochemical Pharmacology (2001), 61(11), 1417-1427
 CODEN: BCPA6; ISSN: 0006-2952
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ab,bib

L3 ANSWER 1 OF 1 CA COPYRIGHT 2002 ACS
 AB We previously reported that oroxylin A, a polyphenolic compound, was a potent inhibitor of lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). In the present study, three oroxylin A structurally related polyphenols isolated from the Chinese herb Huang Qui, namely baicalin, baicalein, and wogonin, were examined for their effects on LPS-induced nitric oxide (NO) production and iNOS and COX-2 gene expressions in RAW 264.7 macrophages. The results indicated that these three polyphenolic compds. inhibited LPS-induced NO production in a concentration-dependent manner without a notable cytotoxic effect on these cells.

The decrease in NO production was in parallel with the inhibition by these polyphenolic compds. of LPS-induced iNOS gene expression. However, these three compds. did not directly affect iNOS enzyme activity. In addition, wogonin, but not baicalin or baicalein, inhibited LPS-induced prostaglandin E2 (PGE2) production and COX-2 gene expression without affecting COX-2 enzyme activity. Furthermore, N-nitro-L-arginine (NLA) and N-nitro-L-arginine Me ester (L-NAME) pretreatment enhanced LPS-induced iNOS (but not COX-2) protein expression, which was inhibited by these three polyphenolic compds. Wogonin, but not baicalin or baicalein, similarly inhibited PGE2 production and COX-2 protein expression in NLA/LPS or L-NAME/LPS-co-treated RAW 264.7 cells. These results indicated that co-treatment with NOS inhibitors and polyphenolic compds. such as wogonin effectively blocks acute production of NO and, at the same time, inhibits expression of iNOS and COX-2 genes.

AN 135:102178 CA
 TI Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide
 AU Chen, Y.-C.; Shen, S.-C.; Chen, L.-G.; Lee, T. J.-F.; Yang, L.-L.
 CS Graduate Institute of Pharmacognosy Science, Taipei Medical University, Taipei, Taiwan
 SO Biochemical Pharmacology (2001), 61(11), 1417-1427
 CODEN: BCPA6; ISSN: 0006-2952
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

WEST**End of Result Set**

Generate Collection

Print

L3: Entry 4 of 4

File: USPT

Jul 24, 2001

DOCUMENT-IDENTIFIER: US 6264995 B1

TITLE: Herbal composition for reducing inflammation and methods of using same

Abstract Text (1):

An herbal composition reducing inflammation in bones and joints by inhibiting the enzyme cyclooxygenase-2 is prepared from holy basil, turmeric, ginger, green tea, rosemary, huzhang, Chinese goldthread, barberry, oregano and scutellariae baicalensis. More particularly, the herbal composition of the present invention contains therapeutically effective amounts of the supercritical extracts of ginger, rosemary and oregano, and therapeutically effective amounts of extracts of holy basil, turmeric, green tea, huzhang, Chinese goldthread, barberry, rosemary and scutellariae baicalensis. The herbal composition can be administered orally, topically or parenterally. Particularly preferred embodiments are soft gel capsules for oral administration and creams for topical application. In addition to reducing inflammation, the herbal composition also promotes healthy joint function and, because it inhibits cyclooxygenase-2 (COX-2), the composition also promotes normal cell growth. Furthermore, the herbal composition contains organic anti-aging constituents that inactivate oxygen free radicals, thereby providing antioxidant benefits in addition to anti-inflammatory benefits.

Brief Summary Text (5):

There are two forms of the cyclooxygenase enzyme: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). The latter form, i.e., COX-2, appears to play a key role in inflammatory processes. Recent scientific studies suggest that inhibiting the COX-2 enzyme may be an effective way to reduce inflammation without the side effects associated with irreversible COX-1 inhibition. In addition, recent scientific studies also suggest that COX-2 inhibition may serve an important function in promoting normal cell growth in the colon, pancreas, breast tissue and other organ systems.

Brief Summary Text (6):

Drugs are being developed which are intended to selectively inhibit COX-2 with minimal effect on COX-1. However, despite the emphasis on COX-2 inhibition, these drugs appear to have serious side effects, e.g., a breakdown in digestive protective mucus and prevention of normal healing processes. For example, non-steroidal anti-inflammatory drugs (NSAIDS) can have a variety of toxic side effects such as, e.g., gastric erosion and adverse effects on kidneys and liver, and may inadequately regulate the cellular immune functions and secretions of various cytokines.

Brief Summary Text (16):

According to various studies, ocimum sanctum (holy basil) possesses significant anti-inflammatory properties and is capable of blocking both the cyclooxygenase and lipoxygenase pathways of arachidonate metabolism. See e.g., J. Ethnopharmacol. April 1999; 65(1):13-9, Evaluation of the Gastric Antiulcer Activity of Fixed Oil of Ocimum Sanctum (Holy Basil), Singh, S. Majundar DK College of Pharmacy, University of Delhi, India; Indian J. Exp. Biol. October 1998; 36(10): 1028-31, Comparative Evaluation of Antiinflammatory Potential of Fixed Oil of Different Species of Ocimum and Its Possible Mechanism of Action, Singh S. College of Pharmacy (University of Delhi), Pushp Vihar, India; J. Ethnopharmacol. October 1996; 54(1):19-26, and Evaluation of Anti-Inflammatory Potential of Fixed Oil of Ocimum Santum (Holy Basil) and Its Possible Mechanism of Action, Singh, S., Majunbar D K, Rehan H M College of Pharmacy (University of Delhi), New Delhi, India. The marker constituents of ocimum sanctum,

i.e., ursolic acid and oleanolic acid (less active) have been found to a significant COX-2 inhibitory effect. See, for example, Indian J. Exp. Biol. April 1997, 35(4):380-3, Evaluation of Antiinflammatory Activity of Fatty Acids of Ocimum Sanctum Fixed Oil, Singh S., Majumdar DK College of Pharmacy (University of Delhi) Pushp Vihar, New Delhi, India; and FEBS Lett. Mar. 16, 1992; 299(3):213-7, Characterization of Ursolic Acid as a Lipoxygenase and Cyclooxygenase Inhibitor Using Macrophages, Platelets and Differentiated HL60 Leukemic Cells, Najid A., Simon A., Cook J., Chable-Rabinovitch H., Delage C., Chulia A J, Rigaud M. CJF INSERM 88-03, Faculte de Medecine, Universite de Limoges, France; J. Nat. Prod. October 1998; 61(10):1212-5, Ursolic Acid from Plantago Major, a Selective Inhibitor of Cyclooxygenase-2 Catalyzed Prostaglandin Biosynthesis, Ringbom T., Segura L., Noreen Y., Perera P., Bohlin L. Division of Pharmacognosy, Department of Pharmacy, Biomedical Centre, Uppsala University, Box 579, S-751 223 Uppsala, Sweden; Cancer Res. Feb. 15, 1998; 58(4):717-23 Novel Triterpenoids Suppress Inducible Nitric Oxide Synthase (iNOS) and Inducible Cyclooxygenase (COX-2) in Mouse Macrophages, Suh N., Honda T., Finlay H. J., Barchowsky A., Williams C., Benoit N. E., Xie Q. W., Nathan C., Gribble G. W., Sporn M. B., Department of Pharmacology and Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, N.H. 03755 USA; Indian J. Exp. Biol. December 1996; 34(12):1212-5, Chemical and Pharmacological Studies on Fixed Oil of Ocimum Sanctum; Singh S., Majumdar D. K., Yadov M. R., College of Pharmacy (University of Delhi) Pushp Vihar, India.; J. Ethnopharmacol November 1987, 21(2):153-63, Ocimum Sanctum: An Experimental Study Evaluating Its Anti-Inflammatory, and Analgesic and Antipyretic Activity in Animals; Godhwani, S., Godhwani, J. L., Vyas D. S., Department of Pharmacology and Experimental Therapeutics, Sandar Patel Medical College, Rajasthan, India.

Brief Summary Text (17):

Curcumin, a major principal of turmeric, has been found to directly inhibit the activity of COX-2. See, e.g., Carcinogenesis March 1999, 20(3):445-51, Curcumin Inhibits Cyclooxygenase-2 Transcription in Bile Acid- and Phorbol Ester-Treated Human Gastrointestinal Epithelial Cells, Zhang F., Altorki N. K., Mestre J. R., Subbaramiah K., Dannenberg A. J., Department of Cardiothoracic Surgery, New York Presbyterian Hospital and Weill Medical College of Cornell University, New York 10021, USA. See also, e.g., Agents Actions October 1982, 12(4):508-15, Anti-Inflammatory and Irritant Activities of Curcumin Analogues in Rats, Mukhopadhyay A., Basu N., Ghatak N., Gujral P. K; and Int J Clin Pharmacol Ther Toxicol December 1986, 24(12):651-4, Evaluation of Anti-Inflammatory Property of Curcumin (Diferuloyl Methxane) in Patients with Postoperative Inflammation, Satoskar R. R., Shah S. J., Shenoy S. G.

Brief Summary Text (18):

Melatonin, a constituent of ginger, has been found to exert potent anti-inflammatory effects via COX-2 inhibition. See, e.g., J Pineal Res August 1999, 27(1):9-14, Regulation of Prostaglandin Production in Carrageenan-Induced Pleurisy by Melatonin, Cuzzocrea S, Costantino G., Mazzon E., Caputi A. P., Institute of Pharmacology, School of Medicine, University of Messina, Italy; Biochem Mol Biol Int March 1995, 35(3):627-34, Identification of Melatonin in Plants and Its Effects on Plasma Melatonin Levels and Binding to Melatonin Receptors in Vertebrates, Hattori A., Migitaka H., Iigo M., Yamamoto K., Ohtani-Kaneko R., Hara M., Suzuki T., Reiter R. J., Department on Anatomy, St. Marianna University School of Medicine, Kawasaki, Japan. See also Biomed Biochim Acta 1984; 43(8-9):S335-46, Aqueous Extracts of Onion, Garlic and Ginger Inhibit Platelet Aggregation and Alter Arachidonic Acid Metabolism, Srivastava K. C.; and Cancer Res Mar. 1, 1996; 56(5):1023-30, Inhibition of Tumor Promotion in SENCAR Mouse Skin by Ethanol Extract of Zingiber Officinale Rhizome, Katiyar S. K., Agarwal R., Mukhtar H., Department of Dermatology, Skin Diseases Research Center, University Hospitals of Cleveland, Case Western Reserve University, Ohio.

Brief Summary Text (22):

In addition, a group of compounds identified as flavan-3-ol derivatives (+)-catechin, rich in green tea, have been identified as COX-1 and COX-2 inhibitors, See, e.g., Planta Med August 1998; 64(6):520-4 Flavan-3-ols isolated from some medicinal plants inhibiting COX-1 and COX-2 catalysed prostaglandin biosynthesis. Noreen Y., Serrano G, Perera P., Bohlin L Department of Pharmacy, Uppsala University, Sweden; J Nat Prod January 1998; 61(1):8-12 Two new isoflavones from Ceiba pentandra and their effect on cyclooxygenase-catalysed prostaglandin biosynthesis. Noreen Y., el-Seedi H, Perera P.,

Bohlin L Department of Pharmacy, Uppsala University, Sweden; J Nat Prod January 1998; 61(1):2-7 Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. Noreen Y., Ringbom T., Perera P., Danielson H, Bohlin L Department of Pharmacy, Uppsala University, Sweden.

Brief Summary Text (23):

Salicylic acid, another constituent of green tea, also has been found to be a COX-2 inhibitor. Reference is made, e.g., to Mol Pharmacol June 1997, 51(6):907-12, Sodium Salicylate Inhibits Cyclo-Oxygenase-2 Activity Independently of Transcription Factor (Nuclear Factor KappaB) Activation: Role of Arachidonic Acid, Mitchell J. A., Saunders M., Barnes P. J., Newton R., Belvisi M. G., Department of Anaesthesia and Critical Care Medicine, The Royal Brompton Hospital, London, England.

Brief Summary Text (24):

Berberine, found in barberry and Chinese goldthread, has been found to inhibit COX-2 without inhibiting COX-1 activity. Reference is made, e.g., to J Ethnopharmacol August 1999; 66(2):227-33 Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells; Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, Fujiwara H Department of Oriental Medicine, Gifu University School of Medicine, Japan; and Biol Pharm Bull August 1998; 21(8):814-7 Inhibitory effect of Coptidis Rhizoma and Scutellariae Radix on azoxymethane-induced aberrant crypt foci formation in rat colon. Fukutake M, Yokota S, Kawamura H, Iisuka A, Amagaya S, Fukuda K, Komatsu Y Central Research Laboratories, Tsumura & Co., Ibaraki, Japan.

Brief Summary Text (26):

Scutellaria baicalensis has been found to possess anti-inflammatory properties. See, e.g., Planta Med April 1995; 61(2):150-3 Pharmacological effects of methanolic extract from the root of Scutellaria baicalensis and its flavonoids on human gingival fibroblast. Chung C P, Park J B, Bae KH College of Dentistry, Seoul National University, Korea.

Brief Summary Text (29):

Rosemary is an antioxidant which may reduce COX-2 expression. Reference is made, e.g., Cancer Res. June 1, 1998; 58(11):2323-7 Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. Chinery R, Beauchamp R D, Shyr Y, Kirkland S C, Coffey R J, Morrow JD Department of Medicine, The Vanderbilt Cancer Center, Vanderbilt University Medical Center, Nashville, Tenn. 37232, USA; J Clin Invest April 1995; 95(4):1669-75 Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. Ferg L, Xia Y, Garcia G E, Hwang D, Wilson CB Department of Immunology, Scripps Research Institute, La Jolla, Calif. 92037, USA.

Brief Summary Text (31):

Scutellaria baicalensis has the ability to scavenge free radicals, Reference is made, e.g., to Z Naturforsch [C] November-December 1997; 52(11-12):817-23 Antioxidant activity of flavones from Scutellaria baicalensis in lecithin liposomes. Gabrielska J, Oszmianski J, Zylka R, Komorowska M Department of Physics and Biophysics, Agricultural University, Norwida, Wroclaw; and Res Commun Mol Pathol Pharmacol October 1995; 90(1):103-14 Protection by baicalein against ascorbic acid-induced lipid peroxidation of rat liver microsomes. Gao D, Sakurai K, Chen J, Ogiso T Shenyang College of Pharmacy, P.R. China.

Brief Summary Text (32):

Although herbal-containing compositions for reducing inflammation are known, it is continually desirable to provide alternative herbal compositions capable of reducing inflammation, particularly by inhibiting COX-2.

Brief Summary Text (33):

Accordingly, a primary object of this invention is to provide an herbal composition capable of effectively reducing bone and joint inflammation by inhibiting COX-2.

Brief Summary Text (41):

The present invention is based on the discovery that an herbal composition composed of

- specific herbs properly extracted and blended in correct proportions will safely and significantly inhibit COX-2, thereby reducing bone and joint inflammation and promoting normal cell growth.

Brief Summary Text (44):

By inhibiting COX-2, the herbal composition of this invention also promotes healthy joint function and normal cell growth.

Detailed Description Text (2):

As stated above, one aspect of the present invention provides an herbal active-ingredient composition which significantly inhibits the COX-2 enzyme, thereby reducing bone and joint inflammation.

Detailed Description Text (5):

Holy Basil (ocimum sanctum) contains the powerful COX-2 inhibitor, ursolic acid, which significantly enhances detoxification and reduces inflammation.

Detailed Description Text (6):

Turmeric contains a unique curcumin phytonutrient complex that naturally inhibits inflammatory COX-2. In addition, turmeric has been shown to possess antioxidant properties. Antioxidant activities diminish free radicals which aggravate the inflammatory response. Furthermore, recent studies have shown that tumeric is synergistic with green tea in that the presence of tumeric significantly multiplies the anti-inflammatory effect of green tea polyphenols.

Detailed Description Text (7):

Ginger inhibits both inflammatory COX-2 and 5-LOX and further functions as antioxidant. In the present invention, the ginger supercritical extract is preferably the supercritical extract of certified organic ginger.

Detailed Description Text (8):

Green tea contains polyphenols which markedly reduce COX-2. Green tea reportedly contains 51 anti-inflammatory phytonutrients.

Detailed Description Text (9):

The dual extracts of rosemary used in the present invention offer highly concentrated, full spectrum COX-2 inhibition and support detoxification.

Detailed Description Text (10):

Huzhang is the richest known source of resveratrol, which has been scientifically shown to inhibit inflammatory COX-2.

Detailed Description Text (11):

The Chinese goldthread and barberry supercritical extracts provide a unique berberine phytonutrient complex which naturally inhibits inflammatory COX-2.

Detailed Description Text (13):

Scutellariae is a unique baicalin phytonutrient complex that naturally inhibits inflammatory COX-2.

WEST

Generate Collection

Print

L3: Entry 3 of 4

File: USPT

May 14, 2002

DOCUMENT-IDENTIFIER: US 6387416 B1
TITLE: Anti-Inflammatory herbal composition and method of use

Brief Summary Text (11):

There are two forms of the cyclooxygenase enzyme: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). The latter form, i.e., COX-2, appears to play a key role in inflammatory processes. Recent scientific studies suggest that inhibiting the COX-2 enzyme may be an effective way to reduce inflammation without the side effects associated with irreversible COX-1 inhibition. In addition, recent scientific studies also suggest that COX-2 inhibition may serve an important function in promoting normal cell growth in the colon, pancreas, breast tissue and other organ systems.

Brief Summary Text (12):

Drugs are being developed which are intended to selectively inhibit COX-2 with minimal effect on COX-1. However, despite the emphasis on COX-2 inhibition, these drugs appear to have serious side effects, e.g., a breakdown in digestive protective mucus and prevention of normal healing processes. For example, non-steroidal anti-inflammatory drugs (NSAIDS) can have a variety of toxic side effects such as, e.g., gastric erosion and adverse effects on kidneys and liver, and may inadequately regulate the cellular immune functions and secretions of various cytokines.

Brief Summary Text (13):

Several herbs have been found to inhibit the COX-2 enzyme.

Brief Summary Text (14):

For example, holy basil has been found to possess significant anti-inflammatory properties and is capable of blocking both the cyclooxygenase and lipoxigenase pathways of arachidonate metabolism. Ursolic acid and oleanolic acid (less active), the marker constituents of holy basil, have been found to a significant COX-2 inhibitory effect.

Brief Summary Text (16):

Scutellaria baicalensis also has been found to inhibit the COX-2 enzyme.

Brief Summary Text (17):

According to the USDA database, green tea contains six constituents having cyclooxygenase-inhibitor activity. According to the Napralert database, green tea contains fifty one constituents having anti-inflammatory activity. The polyphenols in green tea were found to cause a marked reduction in cyclooxygenase-2. Flavan-3-ol derivatives (+)-catechin, also present in green tea, have been reported to be COX-1 and COX-2 inhibitors. In addition, salicylic acid, another constituent of green tea, also has been found to be a COX-2 inhibitor.

Brief Summary Text (18):

Berberine, found in barberry and Chinese goldthread, has been found to inhibit COX-2 without inhibiting COX-1 activity.

Brief Summary Text (20):

Herbs which can scavenge free radicals include, e.g., holy basil, turmeric, huzhang, oregano, and scutellaria baicalensis.

Brief Summary Text (23):

A further object of this invention is to provide the herbal composition set forth in the preceding object, wherein the composition reduces said inflammation by inhibiting COX-2.

Brief Summary Text (36):

The composition of this invention reduces inflammation by inhibiting COX-2. As a result, the composition not only reduces inflammation but also promotes healthy joint function and normal cell growth.

WEST☐ **Generate Collection** **Print**

L3: Entry 2 of 4

File: USPT

May 21, 2002

DOCUMENT-IDENTIFIER: US 6391346 B1

TITLE: Anti-inflammatory, sleep-promoting herbal composition and method of use

Abstract Text (1):

An orally administered composition capable of reducing inflammation in animals, preferably humans, while promoting sleep for such animals, contains a therapeutically effective amount of a post-supercritical carbon dioxide hydroalcoholic extract of ginger, therapeutically effective amounts of supercritical carbon dioxide extracts of hops, chamomile, ginger, valerian and melissa; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, turmeric, scutellaria baicalensis, chamomile and hops. The composition is preferably orally administered on a daily basis for at least about 4 weeks.

Brief Summary Text (11):

There are two forms of the cyclooxygenase enzyme: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). The latter form, i.e., COX-2, appears to play a key role in inflammatory processes. Recent scientific studies suggest that inhibiting the COX-2 enzyme may be an effective way to reduce inflammation without the side effects associated with irreversible COX-1 inhibition. In addition, recent scientific studies also suggest that COX-2 inhibition may serve an important function in promoting normal cell growth in the colon, pancreas, breast tissue and other organ systems.

Brief Summary Text (12):

Drugs are being developed which are intended to selectively inhibit COX-2 with minimal effect on COX-1. However, despite the emphasis on COX-2 inhibition, these drugs appear to have serious side effects, e.g., a breakdown in digestive protective mucus and prevention of normal healing processes. For example, non-steroidal anti-inflammatory drugs (NSAIDS) can have a variety of toxic side effects such as, e.g., gastric erosion and adverse effects on kidneys and liver, and may inadequately regulate the cellular immune functions and secretions of various cytokines.

Brief Summary Text (13):

Several herbs have been found to inhibit the COX-2 enzyme.

Brief Summary Text (14):

For example, holy basil has been found to possess significant anti-inflammatory properties and is capable of blocking both the cyclooxygenase and lipxygenase pathways of arachidonate metabolism. Ursolic acid and oleanolic acid (less active), the marker constituents of holy basil, have been found to a significant COX-2 inhibitory effect.

Brief Summary Text (16):

Scutellaria baicalensis also has been found to inhibit the COX-2 enzyme.

Brief Summary Text (17):

According to the USDA database, green tea contains six constituents having cyclooxygenase-inhibitor activity. According to the Napralert database, green tea contains fifty one constituents having anti-inflammatory activity. The polyphenols in green tea were found to cause a marked reduction in cyclooxygenase-2. Flavan-3-ol derivatives (+)-catechin, also present in green tea, have been reported to be COX-1 and COX-2 inhibitors. In addition, salicylic acid, another constituent of green tea, also has been found to be a COX-2 inhibitor.

Brief Summary Text (18):

Berberine, found in barberry and Chinese goldthread, has been found to inhibit COX-2 without inhibiting COX-1 activity.

Brief Summary Text (20):

Herbs which can scavenge free radicals include, e.g., holy basil, turmeric, and scutellaria baicalensis.

Brief Summary Text (25):

A further object of this invention is to provide the herbal composition set forth in the preceding object, wherein the composition reduces said inflammation by inhibiting COX-2.

Brief Summary Text (33):

Accordingly, one aspect of the present invention is directed to an orally administered herbal composition capable of reducing inflammation in animals, preferably humans, afflicted with inflammation, and further capable of promoting sleep for such animals, the composition being composed of a therapeutically effective amount of a post-supercritical carbon dioxide hydroalcoholic extract of ginger; therapeutically effective amounts of supercritical carbon dioxide extracts of hops, chamomile, ginger (preferably certified organic ginger), valerian and melissa; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, turmeric, scutellaria baicalensis, chamomile and hops.

Brief Summary Text (37):

The composition of this invention reduces inflammation by inhibiting COX-2. As a result, the composition not only reduces inflammation but also promotes healthy joint function and normal cell growth.

Detailed Description Text (3):

The composition of this invention is composed of: a post-supercritical carbon dioxide hydroalcoholic extract of ginger, supercritical carbon dioxide extracts of hops, chamomile, ginger (preferably certified organic ginger), valerian and melissa; and hydroalcoholic extracts of holy basil, turmeric, scutellaria baicalensis, chamomile and hops.

Detailed Description Text (4):

The composition of this invention will contain "therapeutically effective amounts" of the herbal extracts recited above. As used herein with respect to the extracts of ginger, holy basil, turmeric and scutellaria baicalensis, the term "therapeutically effective amount" refers to that amount of the extract which will contribute to the inflammation-reducing ability of the composition. With respect to the extracts of melissa, valerian, hops and chamomile, the term "therapeutically effective amount" means that amount of the herb which will promote sleep without interfering with the composition's anti-inflammatory properties. Preferably, the composition of this invention contains:

Detailed Description Text (13):

(I) from about 12% to about 18%, more preferably from about 13% to about 17%, by weight of the hydroalcoholic extract of scutellaria baicalensis;

Detailed Description Text (19):

The hydroalcoholic extracts of holy basil, turmeric, scutellaria baicalensis, hops and chamomile used in the present invention can be prepared according to conventional hydroalcoholic extraction techniques. For example, the hydroalcoholic extracts can be prepared by extracting the plant portion in a water/alcohol (preferably water/ethanol) mixture (preferably composed of 60-80 parts alcohol and 40-20 parts water), and then evaporating off the water/alcohol liquid, leaving a powdered extract residue (referred to herein as "the hydroalcoholic extract").

Detailed Description Paragraph Table (1):

TABLE Ingredient Amount Holy Basil (leaf), extract 150 mg (2% ursolic acid - 2 mg) Valerian, valeriana officinalis and 20 mg Valeriana mexicanus (root) Supercritical CO.sub.2 extract (60% valepotriates - 12 mg) Melissa (leaf) 85 mg Supercritical

CO.sub.2 extract (1% essential oil - 0.85 mg) (including neral and geranial) Turmeric (rhizome), extract 100 mg (7% curcumin - 7 mg) Scutellaria baicalensis (root), extract 5:1 100 mg Ginger (rhizome), 61.5 mg (post-supercritical CO.sub.2 ethanolic extract) (3% pungent compounds - 1.8 mg) Ginger, certified organic (rhizome) 13.5 mg Supercritical CO.sub.2 extract, (30% pungent compounds - 4 mg, 8% zingiberene - 1 mg) Chamomile (flower), supercritical CO.sub.2 extract 50 mg (minimum 25% alpha-bisabolol - 12.5 mg) Hops (strobiles), supercritical CO.sub.2 extract 50 mg (35% humulones - 17 mg) (12% lupulones - 6 mg) Hops (strobiles), ethanolic extract 25 mg (1.5% xanthohumol - 0.37 mg) Chamomile (flower), extract 25 mg (minimum 3% apigeninglycosides - 0.75 mg) Olive Oil, certified organic Yellow Beeswax

CLAIMS:

1. An orally administered composition for reducing inflammation in animals while also promoting sleep for the animals, comprising: a therapeutically effective amount of a post-supercritical carbon dioxide hydroalcoholic extract of ginger; therapeutically effective amounts of supercritical carbon dioxide extracts of hops, chamomile, ginger, valerian and melissa; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, turneric, scutellaria baicalensis, chamomile and hops.

2. A composition according to claim 1, comprising:

(A) from about 7% to about 11% by weight of the post-supercritical carbon dioxide hydroalcoholic extract of ginger;

(B) from about 1% to about 3% by weight of the supercritical carbon dioxide extract of ginger;

(C) from about 5.5% to about 8.5% by weight of the supercritical carbon dioxide extract of chamomile;

(D) from about 5.5% to about 8.5% by weight of the supercritical carbon dioxide extract of hops;

(E) from about 18% to about 26% by weight of the hydroalcoholic extract of holy basil;

(F) from about 2.0% to about 4.0% by weight of the supercritical carbon dioxide extract of valerian;

(G) from about 10% to about 16% by weight of the supercritical carbon dioxide extract of melissa;

(H) from about 12% to about 18% by weight of the hydroalcoholic extract of turmeric;

(I) from about 12% to about 18% by weight of the hydroalcoholic extract of scutellaria baicalensis;

(J) from about 2.5% to about 4.5% by weight of the hydroalcoholic extract of chamomile; and

(K) from about 2.5% to about 4.5% by weight of the hydroalcoholic extract of hops.

3. A composition according to claim 1, comprising:

(A) from about 8% to about 10% by weight of a post-supercritical carbon dioxide hydroalcoholic extract of ginger;

(B) from about 1.5% to about 2.5% by weight of the supercritical carbon dioxide extract of ginger;

(C) from about 6% to about 8% by weight of the supercritical carbon dioxide extract of chamomile;

(D) from about 6% to about 8% by weight of the supercritical carbon dioxide extract of

hops;

(E) from about 20% to about 24% by weight of the hydroalcoholic extract of holy basil;

(F) from about 2.5% to about 3.5% by weight of the supercritical extract of valerian;

(G) from about 11% to about 15% by weight of the supercritical extract of melissa;

(H) from about 13% to about 17% by weight of the hydroalcoholic extract of turmeric;

(I) from about 13% to about 17% by weight of the hydroalcoholic extract of scutellaria baicalensis;

(J) from about 3% to about 4% by weight of the hydroalcoholic extract of chamomile;
and

(K) from about 3% to about 4%, by weight of the hydroalcoholic extract of hops.

17. A composition according to claim 1, wherein the composition comprises:

(A) from about 7% to about 11% by weight of the post-supercritical carbon dioxide hydroalcoholic extract of ginger, wherein the extract comprises from about 2% to about 4% by weight of pungent compounds;

(B) from about 1% to about 3% by weight of the supercritical carbon dioxide extract of ginger, wherein the extract comprises from about 20% to about 40% by weight of pungent compounds and from about 7% to about 9% by weight of zingiberene;

(C) from about 5.5% to about 8.5% by weight of the supercritical carbon dioxide extract of chamomile, wherein the extract comprises at least about 25% by weight of alpha-bisabolol;

(D) from about 5.5% to about 8.5% by weight of the supercritical carbon dioxide extract of hops, wherein the extract comprises from about 30% to about 40% by weight of humulones, and from about 9% to about 15% by weight of lupulones;

(E) from about 18% to about 26% by weight of the hydroalcoholic extract of holy basil, wherein the extract comprises from about 1% to about 3% by weight of ursolic acid;

(F) from about 2.0% to about 4.0% by weight of the supercritical carbon dioxide extract of valerian, wherein the extract comprises from about 50% to about 70% by weight of valepotriates;

(G) from about 10% to about 16% by weight of the supercritical carbon dioxide extract of melissa, wherein the extract comprises from about 0.5% to about 2% by weight of essential oil;

(H) from about 12% to about 18% by weight of the hydroalcoholic extract of turmeric, wherein the extract comprises from about 5% to about 9% by weight of curcumin;

(I) from about 12% to about 18% by weight of the hydroalcoholic extract of scutellaria baicalensis;

(J) from about 2.5% to about 4.5% by weight of the hydroalcoholic extract of chamomile, wherein the extract comprises at least about 3% by weight of apigeninglycosides; and

(K) from about 2.5% to about 4.5% by weight of the hydroalcoholic extract of hops, wherein the extract comprises from about 1% to about 2% by weight of xanthohumol;

further wherein the composition comprises: (i) the post-supercritical carbon dioxide hydroalcoholic extract of ginger and the supercritical carbon dioxide extract of ginger at a weight ratio of from about 4 to about 5 parts of post-supercritical carbon dioxide hydroalcoholic extract per 1 part of supercritical carbon dioxide extract;

(ii) the supercritical carbon dioxide extract of chamomile and the hydroalcoholic extract of chamomile in a weight ratio of from about 1.75 to about 2.25 parts of the supercritical carbon dioxide extract per 1.0 part of the hydroalcoholic extract, and
(ii) the supercritical carbon dioxide extract of hops and the hydroalcoholic extract of hops in a weight ratio of from about 1.75 to about 2.25 parts of the supercritical carbon dioxide extract per 1.0 part of the hydroalcoholic extract.

20. A method according to claim 19, wherein the composition provided in step (1) comprises:

- (A) from about 7% to about 11% by weight of the post-supercritical carbon dioxide hydroalcoholic extract of ginger;
- (B) from about 1% to about 3% by weight of the supercritical carbon dioxide extract of ginger;
- (C) from about 5.5% to about 8.5% by weight of the supercritical carbon dioxide extract of chamomile;
- (D) from about 5.5% to about 8.5% by weight of the supercritical carbon dioxide extract of hops;
- (E) from about 18% to about 26% by weight of the hydroalcoholic extract of holy basil;
- (F) from about 2.0% to about 4.0% by weight of the supercritical extract of valerian;
- (G) from about 10% to about 16% by weight of the supercritical extract of melissa;
- (H) from about 12% to about 18% by weight of the hydroalcoholic extract of turmeric;
- (I) from about 12% to about 18% by weight of the hydroalcoholic extract of scutellaria baicalensis;
- (J) from about 2.5% to about 4.5% by weight of the hydroalcoholic extract of chamomile; and
- (K) from about 2.5% to about 4.5% by weight of the hydroalcoholic extract of hops.

21. A method according to claim 19, wherein the composition provided in step (1) comprises:

- (A) from about 8% to about 10% by weight of a post-supercritical carbon dioxide hydroalcoholic extract of ginger;
- (B) from about 1.5% to about 2.5% by weight of a supercritical carbon dioxide extract of ginger;
- (C) from about 6% to about 8% by weight of a supercritical carbon dioxide extract of chamomile;
- (D) from about 6% to about 8% by weight of a supercritical carbon dioxide extract of hops;
- (E) from about 20% to about 24% by weight of the hydroalcoholic extract of holy basil;
- (F) from about 2.5% to about 3.5% by weight of the supercritical extract of valerian;
- (G) from about 11% to about 15% by weight of the supercritical extract of melissa;
- (H) from about 13% to about 17% by weight of the hydroalcoholic extract of turmeric;
- (I) from about 13% to about 17% by weight of the hydroalcoholic extract of scutellaria baicalensis;

(J) from about 3% to about 4% by weight of the hydroalcoholic extract of chamomile;
and

(K) from about 3% to about 4%, by weight of the hydroalcoholic extract of hops.

35. A method according to claim 19, wherein the composition provided in step (1) comprises:

(A) from about 7% to about 11% by weight of the post-supercritical carbon dioxide hydroalcoholic extract of ginger, wherein the extract comprises from about 4% to about 6% by weight of pungent compounds;

(B) from about 1% to about 3% by weight of the supercritical carbon dioxide extract of ginger, wherein the extract comprises from about 20% to about 40% by weight of pungent compounds and from about 7% to about 9% by weight of zingiberene;

(C) from about 5.5% to about 8.5% by weight of the supercritical carbon dioxide extract of chamomile, wherein the extract comprises at least about 25% by weight of alpha-bisabolol;

(D) from about 5.5% to about 8.5% by weight of the supercritical carbon dioxide extract of hops, wherein the extract comprises from about 30% to about 40% by weight of humulone, and from about 9% to about 15% by weight of lupulones;

(E) from about 18% to about 26% by weight of the hydroalcoholic extract of holy basil, wherein the extract comprises from about 1% to about 3% by weight of ursolic acid;

(F) from about 2.0% to about 4.0% by weight of the supercritical extract of valerian, wherein the extract comprises from about 50% to about 70% by weight of valepotriates;

(G) from about 10% to about 16% by weight of the supercritical extract of melissa, wherein the extract comprises from about 0.5 to about 2% by weight of essential oil;

(H) from about 12% to about 18% by weight of the hydroalcoholic extract of turmeric, wherein the extract comprises from about 5% to about 9% by weight of curcumin;

(I) from about 12% to about 18% by weight of the hydroalcoholic extract of scutellaria baicalensis;

(J) from about 2.5% to about 4.5% by weight of the hydroalcoholic extract of chamomile, wherein the extract comprises at least about 3% by weight of apigeninglycosides; and

(K) from about 2.5% to about 4.5% by weight of the hydroalcoholic extract of hops, wherein the extract comprises from about 1% to about 2% by weight of xanthohumol;

further wherein the composition comprises: (i) the post-supercritical carbon dioxide hydroalcoholic extract of ginger and the supercritical carbon dioxide extract of ginger at a weight ratio of from about 4 to about 5 parts of post-supercritical carbon dioxide hydroalcoholic extract per 1 part of supercritical carbon dioxide extract; (ii) the supercritical carbon dioxide extract of chamomile and the hydroalcoholic extract of chamomile in a weight ratio of from about 1.75 to about 2.25 parts of the supercritical carbon dioxide extract per 1.0 part of the hydroalcoholic extract, and (iii) the supercritical carbon dioxide extract of hops and the hydroalcoholic extract of hops in a weight ratio of from about 1.75 to about 2.25 parts of the supercritical carbon dioxide extract per 1.0 part of the hydroalcoholic extract.

WEST☐ **Generate Collection** **Print**

L3: Entry 1 of 4

File: USPT

Nov 5, 2002

DOCUMENT-IDENTIFIER: US 6475530 B1
TITLE: Methods and compositions for producing weight loss

Abstract Text (1):

Disclosed are methods and compositions for producing weight loss in a mammal by administration of a composition containing a weight loss effective amount of a noradrenaline stimulating compound such as ephedrine, mahuang (a plant source of ephedrine alkaloids), citrus aurantium (bitter orange), synephrine, norephedrine, psuedophedrine, a methylxanthine, such as caffeine or guarana, and a botanical COX inhibitor such as resveratrol, polygonum cuspidatum, scutellaria baicalensis, turmeric, curcumin, rosmary, green tea, ocimum sanctum (holy basil), or ginger, instead of an NSAID such as aspirin, and optionally a free fatty acid reducing compound. The thermogenic formula is coupled with a growth hormone stimulating formulation containing L-arginine or L-omithine, L-lysine, and a free fatty acid reducing agent such as nicotinic acid. The thermogenic formula would preferably be administered in the daytime, and the growth hormone producing formula at nighttime. The two compositions form a system of AM and PM weight loss strategy for the therapeutic intervention of obesity.

Brief Summary Text (12):

A much safer and more effective composition for the thermogenic triad would be the use of a COX inhibitor other than aspirin. COX-2, or cyclooxygenase-2 inhibitors inhibit cyclooxygenase and reduce prostaglandins without producing the degree of gastric erosion associated with NSAID drugs such as aspirin. However, many COX-2 inhibitors have a short half-life, and do not keep prostaglandins suppressed completely or in a prolonged fashion over a 6-24 hour period. In addition, the turnover rate for cyclooxygenase is fairly short.

Brief Summary Text (13):

Another attempt to formulate a weight loss product is described in U.S. Pat. No. 5798101. This patent is directed to herbal compositions to reduce weight and help suppress appetite consisting of St. John's Wort and ephedra with or without caffeine. These formulations do not include a prostaglandin inhibitor such as aspirin or a COX-2 inhibitor, so the thermogenic component (the ephedra) would be less effective at driving metabolism because of the negative feedback from prostaglandins. The St John's Wort is present to produce an effect on serotonin, a neurotransmitter involved in mood and carbohydrate craving. Thus, its function in the formulations described in this patent is as an appetite suppressant, not as a component in the thermogenic triad of ephedra, aspirin, and caffeine.

Brief Summary Text (29):

In its broadest sense, the present invention is directed to a method for producing weight loss in a mammal by administering a composition containing a weight loss effective amount of a noradrenaline stimulating compound such as ephedrine, mahuang (a plant source of ephedrine alkaloids), citrus aurantium (bitter orange), synephrine, norephedrine, psuedophedrine, a methylxanthine, such as caffeine or guarana, and a COX-2 inhibitor such as resveratrol, polygonum cuspidatum, scutellaria baicalensis, white willow bark, turmeric, curcumin, rosmary, green tea, ocimum sanctum (holy basil), or ginger, instead of an NSAID such as aspirin. The preferred COX-2 inhibitor would be resveratrol from a botanical source such as polygonum cuspidatum or polygonum multiflorum.

Brief Summary Text (30):

Polygonum cuspidatum, a member of the buckwheat family (polygonaceae), commonly known as Japanese knotweed. This plant is a native of eastern Asia, but also grows wild throughout northeastern America and southern Canada. The roots Polygonum cuspidatum contain a large amount of resveratrol, a stilbene which is a powerful anti-oxidant, and exhibits anti-inflammatory, anti-mutagen, and anti-carcinogenic properties. Resveratrol also inhibits blood platelet aggregation, making it a beneficial cardiovascular compound. Recently, resveratrol was found to inhibit COX-2 by dose dependently reducing prostaglandin, E-2 (PGE2) production in human mammary epithelial cells. The dried roots of Polygonum cuspidatum contain about 5-8% resveratrol. By using various extracting techniques to concentrate the amount of resveratrol in Polygonum cuspidatum, high yield powders have been obtained that contain up to 20% resveratrol. Therefore, 100 mg. of Polygonum cuspidatum extract will deliver 20 mg. of actual resveratrol. Synthetic resveratrol is available, but it is extremely expensive, about \$250.00 per gram.

Brief Summary Text (34):

In general, the amount of ephedrine would be about 20-350 mg. per day, preferably about 25-100 mg. per day. The amount of caffeine or caffeine containing botanical yielding 10-500 mg./day, preferably about 20-200 mg./day. The amount of resveratrol or botanical source of resveratrol would yield from 1-500 mg. per day of actual resveratrol. Other COX-2 inhibitors must be used at a level that significantly inhibits the COX-2 enzyme, or enough to reduce prostaglandin synthesis sufficient to overcome feedback inhibition of the thermogenesis initiated by the noradrenaline stimulating agent. Nicotinic acid or analogues, esters, or pro-drugs of nicotinic acid may optionally be added to the thermogenic daytime formula. The components in the thermogenic triad may be in immediate-release form or sustained-release form. The ingredients are preferably in sustained-release form as this prolongs the metabolic activity and reduces the potential for side-effects that may arise from "spiking" or a rapid rise in blood levels of the respective compounds if given in immediate-release form.

Other Reference Publication (1):

Lane, N. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors, 1997, The Journal of Rheumatology, vol. 24, Supplement 49, pp. 20-24.*

CLAIMS:

1. A weight loss composition comprising: a thermogenic noradrenaline generating substance containing at least one compound selected from the group consisting of ephedrine, synephrine and pharmaceutically acceptable salts thereof; a COX-2 inhibitor; and a methylxanthine.
2. The composition of claim 1, wherein the COX-2 inhibitor is derived from a botanical.
3. The composition of claim 2, wherein the botanical is selected from the group consisting of Polygonum cuspidatum, Polygonum multiflorum, Scutellaria baicalensis, white willow bark, turmeric, curcumin, rosemary, green tea, Ocimum sanctum (holy basil), and ginger.
5. The composition of claim 1, wherein the COX-2 inhibitor is resveratrol that is derived from Polygonum cuspidatum or Polygonum multiflorum.